The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Status:
Completed
Trial end date:
2020-04-29
Target enrollment:
Participant gender:
Summary
This randomised, double-blind, placebo-controlled, phase 2 study aims to evaluate the
efficacy and safety of the anti-fibrotic drug pirfenidone in the treatment of patients with
heart failure and preserved left ventricular ejection fraction (HFpEF). Participants will be
randomised to receive either pirfenidone or placebo, for a period of 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
Manchester University NHS Foundation Trust University Hospital of South Manchester NHS Foundation Trust
Collaborators:
Hoffmann-La Roche National Institute for Health Research, United Kingdom Roche Therapeutics Ltd University of Liverpool, Clinical Trials Research Centre University of Manchester